The impact of combined oral contraceptives on ocular tissues: a review of ocular effects
review
OA: gold
CC0
AI-generated summary
This review examines combined oral contraceptives' actions and adverse effects on ocular tissues, noting rare complications like dry eye and retinal issues, with potential prevention through estrogen dosage adjustment or progestin choice.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The aim of this manuscript is to review the action and adverse effects of combined oral contraceptives (COCs) on ocular tissues. The percentage of unwanted pregnancies and the subsequent abortions make contraception crucial worldwide. Over 100 million women around the world use common contraceptive methods, including intrauterine devices, combined estrogen and progestin oral contraceptives, as well as progestin only preparations (oral contraceptives, implants or injections). COCs are widely used for contraception, but they are also indicated in menorrhagia, endometriosis, acne and hirsutism, fibroid uterus and premenstrual syndrome. However, they have been associated with high rates of cardiovascular events, venous thromboembolic disease, ischemic strokes and breast cancer. The incidence of COCs-related ocular complications is estimated to be 1 in 230 000, including dry eye symptoms, corneal edema, lens opacities and retinal neuro-ophthalmologic or vascular complications. We may infer that the serious ocular complications of COCs can be prevented by eliminating the estrogen dosage and choosing third-generation progestins. In any case, doctors should take into consideration the systemic and ocular history of the patients before selecting any method of contraception.
My notes (saved in your browser only)
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (1)
References (64)
- Selective progesterone receptor modulators in reproductive medicine: pharmacology, clinical efficacy and safety via openalex
- W44000797 via openalex
- W83895962 via openalex
- W112784718 via openalex
- W173465249 via openalex
- W195929944 via openalex
- W1455556971 via openalex
- W1521403948 via openalex
- W1543443896 via openalex
- W1964292893 via openalex
- W1972397264 via openalex
- W1977913185 via openalex
- W1981705949 via openalex
- W1981764416 via openalex
- W1986188020 via openalex
- W1986910701 via openalex
- W2001654548 via openalex
- W2009242975 via openalex
- W2017117077 via openalex
- W2018599351 via openalex
- W2026108022 via openalex
- W2029567957 via openalex
- W2036762985 via openalex
- W2039564721 via openalex
- W2052297954 via openalex
- W2052624175 via openalex
- W2060182030 via openalex
- W2060571746 via openalex
- W2063383467 via openalex
- W2068201500 via openalex
- W2073657341 via openalex
- W2082288519 via openalex
- W2082690685 via openalex
- W2083014828 via openalex
- W2084414024 via openalex
- W2101656247 via openalex
- W2104662666 via openalex
- W2116804632 via openalex
- W2131736745 via openalex
- W2137194916 via openalex
- W2138987017 via openalex
- W2144509180 via openalex
- W2144878948 via openalex
- W2151568619 via openalex
- W2165501853 via openalex
- W2167185476 via openalex
- W2168509987 via openalex
- W2168987809 via openalex
- W2179475984 via openalex
- W2198960143 via openalex
- W2266879013 via openalex
- W2288231068 via openalex
- W2289249449 via openalex
- W2289941100 via openalex
- W2291430735 via openalex
- W2299436814 via openalex
- W2304069655 via openalex
- W2410808871 via openalex
- W2417095026 via openalex
- W2428369610 via openalex
- W2472548969 via openalex
- W3149174683 via openalex
- W10801075 via openalex
- W4290147089 via openalex
Source provenance
- europepmc
- last seen: 2026-09-12T06:14:40.653888+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-05-13T22:20:13.663096+00:00
License: CC0
· commercial use OK